title: CuraGen Corporation.
abstract: CuraGen Scientists have developed a deep preclinical pipeline of potential protein, antibody and small molecule therapeutics by integrating expertise in molecular biology with a proprietary suite of functional genomic technologies. One important application of functional genomics is in the area of pharmacogenomics, which has been a critical component in CuraGen's drug discovery and development efforts. By identifying safety and efficacy issues early in the discovery process and by gaining a better understanding of a drug's mechanism of action, CuraGen scientists are able to make more informed decisions about which drugs are the most appropriate to advance through the preclinical and clinical development stages.
authors.affiliation: CuraGen Corporation, 555 Long Wharf Drive, New Haven, CT 06511, USA.
authors.forename: Traci
authors.initials: T
authors.lastname: Mansfield
authors.forename: Mark R
authors.initials: MR
authors.lastname: Vincent
mesh_terms: D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D006801:Humans; D008967:Molecular Biology; D010597:Pharmacogenetics